Is BPC-157 legal? What FDA, HHS and the anti-doping rules say in 2026

Is BPC-157 legal?

BPC-157 is not an approved drug: USADA notes it is not approved for human clinical use by FDA or any other health authority. Since October 30, 2026, a draft HHS policy says HHS will not act against licensed 503A pharmacies or physicians compounding it under strict conditions. Products sold as research chemicals or supplements are outside that policy.

The short answer has two parts. First, BPC-157 is not an approved drug: it is not approved for human clinical use by the U.S. Food and Drug Administration or any other global health authority [5]. No company can sell it as an approved medicine, because none exists.

Second, there is now one route the federal government has described. On October 30, 2026, HHS published a draft enforcement discretion policy: it does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product with one of the peptides in the policy's Appendix A, while the 503A bulks list is developed through rulemaking [1]. BPC-157 acetate is one of the six peptides it covers [2].

That policy does not apply to products sold as research chemicals or dietary supplements [2]. So the sections below take each way people meet BPC-157, an approved drug, a compounding pharmacy, a research vial or a supplement, and a sports test, and say what the sources show about each.

Is BPC-157 FDA approved?

No. BPC-157 has never been approved by FDA for any use. FDA lists it among substances whose compounded drugs may pose a risk for immunogenicity, with only limited safety information for the proposed routes. USADA adds that no human clinical trials establish its efficacy for any diagnosis or treatment.

No. BPC-157 is not approved for human clinical use by FDA or any other global health authority [5]. Approval would mean FDA had reviewed a manufacturer's evidence that a specific product is safe and effective for a specific use, and no such review has happened.

FDA's own concerns are on its page of bulk substances that may present significant safety risks in compounding. Its BPC-157 entry says compounded drugs containing it may pose risk for immunogenicity (an immune reaction against the peptide) for certain routes of administration, may have complexities with peptide-related impurities and characterization of the active ingredient, and that FDA has identified no, or only limited, safety-related information for the proposed routes of administration [3]. That page now lists BPC-157 under bulk drug substances nominated but withdrawn, previously in category 2 [3].

The evidence gap behind that is plain in USADA's summary: there are several animal studies, but no human clinical trials establishing efficacy for the use of BPC-157 for any diagnosis or treatment [5]. It has been investigated for inflammatory bowel disease and soft tissue healing, mainly in animal models, and USADA describes a concerning lack of published human clinical trial data, because studies appear to have been cancelled or stopped without any published conclusions [5]. Our guide to FDA-approved peptides lists the peptides that did go through approval.

Can a pharmacy compound BPC-157?

Under a draft HHS policy, a licensed 503A pharmacy or physician can compound BPC-157 acetate for injection under the skin or into muscle, or as an oral or topical product, without HHS enforcement, if strict conditions are met. The policy is interim, non-binding and not FDA approval. Outsourcing facilities under 503B are not covered.

Until 2026, effectively no. In 2023 BPC-157 was among the peptides FDA effectively barred compounding pharmacies from dispensing, saying they may present significant safety risks [4].

In 2026 that changed. On July 23, an FDA advisory committee voted on whether BPC-157 belongs on the 503A bulks list: eight members voted yes, six voted no, and one abstained [4]. FDA staff had written that the evaluation criteria weigh against listing it, citing limited evidence of effectiveness [4], and FDA is not required to follow advisory committee recommendations, though it typically does [6].

The vote was about narrow uses. The committee was tasked with reviewing data supporting specific conditions, such as BPC-157 for treating ulcerative colitis, an inflammatory bowel disease [6]. The only effectiveness trial FDA staff could find for that use was a meeting abstract reporting a study in 46 people in which the peptide was given as an enema, not as an injection [4]. NPR notes that if FDA ultimately reclassifies these peptides and compounding pharmacies make them, clinicians would have discretion to prescribe outside those narrow indications [6].

Then, on October 30, 2026, HHS published its draft enforcement discretion policy [1]. For BPC-157 acetate it covers subcutaneous, intramuscular, oral and topical dosage forms [2]. The conditions include [2]:

• A licensed pharmacist or licensed physician compounds the product.
• The bulk peptide comes from an FDA-registered manufacturer that complies with current good manufacturing practice, with a valid certificate of analysis.
• A valid patient-specific prescription, and a single active ingredient from the list (no blends).
• Serious adverse events and product quality issues are reported to FDA's MedWatch program and state authorities.
• The label says "This is a compounded drug product. Not for resale.", and an oral form needs documentation of adequate bioavailability.

What it does not do matters as much. The notice says the policy does not establish any rights for any person and is not binding on HHS or the public, and HHS may revisit it if a safety signal or product quality issue arises [1]. It is not FDA approval and does not apply to 503B outsourcing facilities [2]. Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed [1].

What comes next is rulemaking. HHS writes that FDA's future rulemakings may propose adding some or all of these peptides to the 503A bulks list based on the available evidence [1]. Our FDA peptide reclassification explainer follows the whole process for all twelve peptides.

Is research use only or supplement BPC-157 legal?

The 2026 changes do not reach it. The HHS policy expressly does not apply to products sold as research chemicals or dietary supplements, and it covers only drugs compounded by licensed pharmacists or physicians from registered, tested sources on a patient-specific prescription. A vial labeled for research, or a capsule sold as a supplement, gets no cover from it.

Much of the BPC-157 in circulation is sold online as a research peptide or as a supplement. The HHS policy says, in so many words, that it does not apply to products sold as research chemicals or dietary supplements [2]. Its conditions describe a different product: compounded by a licensed pharmacist or physician, from a bulk substance made by an FDA-registered, CGMP-compliant manufacturer with a certificate of analysis, on a patient-specific prescription [2].

USADA puts the quality problem in the same terms from the athlete's side: because BPC-157 has not been extensively studied in humans, it is unknown whether there is a safe dose, or any way to use it safely to treat a specific medical condition [5]. If you are trying to judge a research vial anyway, our guide to vetting research peptides covers what a certificate of analysis does and does not prove.

Is BPC-157 banned in sports?

Yes. USADA states that BPC-157 is prohibited under the World Anti-Doping Agency Prohibited List in the S0 Non-Approved Substances category. A therapeutic use exemption is unlikely to be approved, USADA says, because permitted alternatives exist. The 2026 compounding policy does not change its status in sport.

For athletes the answer does not depend on the compounding debate. USADA states that BPC-157 is prohibited under the WADA Prohibited List in the category of S0 Non-Approved Substances [5].

On a therapeutic use exemption (TUE), USADA says one is unlikely to be approved because there are permitted alternatives available, though it considers each application case by case [5]. A prescription from a compounding pharmacy is not an exemption. Athletes in tested sport, including school and college athletes, should ask their anti-doping organization before using it.